Prakash Achaary
Helping to Accelerate the Search for Solutions to the COVID-19 Crisis
By Rob DiCicco, June 11, 2020
The novel coronavirus (COVID-19) pandemic is an unprecedented crisis that has galvanized the global scientific community around the search for a viable vaccine and effective therapies. This incredible commitment to science may ultimately pay dividends, but each passing day is critical as we seek to stem the tide of this deadly pandemic. There is a collective sense of urgency to consider incremental ways to expediate the process to get treatments to patients and our IBM® Clinical Development (ICD) solution is designed to help address a challenge such as this.
IGY Life Sciences Partners with MMS Holdings to Develop Novel COVID-19 Antibody Treatment
THUNDER BAY, ONTARIO (June 08, 2020) – IGY Life Sciences today announced it will be collaborating with clinical data and regulatory experts, MMS Holdings (MMS), to further the development of IgY-110, an anti-CoV2 therapeutic antibody with a focus on a nasal spray application. This novel approach of an IgY antibody in a nasal spray will be complementary to any vaccine developed.
University of Michigan School of Information Invites MMS Holdings Executive Kelly J. Hill to Join External Advisory Board
CANTON, Mich. (May 19, 2020) – MMS Holdings Inc. (MMS) – an award-winning, data-focused CRO – announced today that its Executive Director of Global Business Operations and Strategy Kelly J. Hill has accepted an invitation to join the University of Michigan School of Information (UMSI) External Advisory Board (EAB).
Green Valley Pharmaceutical And MMS Holdings Collaborate to Gain FDA Approval To Begin Clinical Trial For The First Alzheimer’s Drug In 17 Years
CANTON, Mich. and SHANGHAI (May 5, 2020) – MMS announced that a successful collaboration with Shanghai-based Green Valley Pharmaceutical Co. (Green Valley) resulted in gaining U.S. Food & Drug Administration (FDA) approval of an Investigational New Drug (IND) application for the GV-971 international multi-center Phase III clinical study in the treatment of patients with Alzheimer’s disease.
MMS Announces One Million Dollar Award For Pharmaceutical Companies Developing A Vaccine For COVID-19
Canton, Mich. (March 20, 2020) — MMS Holdings announced today that it is offering a USD1M award toward the development of a vaccine for COVID-19, also known as the coronavirus. The award is being offered in the form of data and related services to qualified pharmaceutical and clinical research companies supporting the commercial development of a vaccine for approval in the United States and/or other global health authorities.
Committed to the health of your projects during COVID-19
MMS Holdings To Debut Datacise Integrated Safety Explorer To Detect Safety Signals
CANTON, Mich. (March 4, 2020) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today that the Datacise Integrated Safety Explorer will make its debut at the 2020 PHUSE U.S. Connect conference in Orlando, Florida as part of the PHUSE/FDA Data Science Innovation Challenge, where, according to PHUSE, the “greatest minds in the data sciences arena come together and collaborate.”
MMS Holdings Doubles Growth In South Africa Region
BLOEMFONTEIN, South Africa (November 20, 2019) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced today that its regional operations in South Africa has more than doubled in the past fiscal year, through the addition of new colleagues in Bloemfontein and the successful procurement of key contracts with clinical trial sponsors and research groups.
MMS Holdings Executive Michelle Gayari Joins Advisory Board of International Nonprofit
CANTON, Mich. (October 23, 2019) – MMS Holdings – an award-winning, data-focused CRO – announced today that its Executive Director of Global Operations Michelle Gayari has joined the advisory board for the international 501(c)(3) charity Together Educating All Children in Hospitals (TEACH). As its sole board member in the state of Michigan, Gayari will provide leadership, guidance, and fundraising support to help in bringing exciting, hands-on educational programs to children in hospitals.
MMS Holdings Announces Status As A Finalist For Best Contract Research Organization
CANTON, Mich. (October 10, 2019) – MMS Holdings (MMS) – an award-winning, data-focused CRO – announced its recognition as a finalist in the highly-esteemed, global Scrip Awards by Informa Pharma Intelligence as Best Contract Research Organization – Specialist Providers at the 10th Annual MMS Scientific Symposium.
Oracle Health Sciences and MMS Collaborate to Deliver Complex Database Build for Oncology Sponsor
CANTON, Mich. (September 30, 2019) – MMS Holdings (MMS) – an award-winning, data-focused CRO – celebrated another successful collaboration with Oracle Health Sciences and a specialized Oncology pharmaceutical company. MMS will share their learnings with peers at the Society for Clinical Data Management (SCDM) annual meeting in Baltimore, Md.